Jean-Paul Vilaine

This inventor holds 28 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Adir Et Compagnie, Les Laboratoires Servier, Adir Et Cie. Active years: 1988-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Paul Vilaine. Retrieved from https://idiyas.com/inventor/jean-paul-vilaine

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 1)

% Patents Active = 82.1

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.9

ph-index = 7

Forward Citations = 174(Granted Patents)

Location History:

Le Plessis Robinson, FR (1988 - 1989)
Chatenay, FR (1993)
Chatenay Malabry, FR (1991 - 2017)

Company Filing History:

Les Laboratoires Servier

Les Laboratories Servier

patents

Years Active: 1988-2017

Loading Chart...

Areas of Expertise:

Isoquinoline Compounds

Cyclic Ureas

Sulfonamides

Benzazepine Compounds

Dihydropyridine Compounds

Phenoxyalkanoic Acids

Angiopeptin Cyclopeptides

Flavones

Aminochromanol Compounds

Anti-Hypertensive Compounds

Spiro Compounds

Piperidine Compounds

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9809553 - Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them (2017-11-07),

2. 8076325 - 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them (2011-12-13),

3. 6908922 - Linear cyclic ureas (2005-06-21),

4. 6903103 - Linear cyclic ureas (2005-06-07),

5. 6780868 - Linear cyclic ureas (2004-08-24),

6. 6696469 - Cyclobutenedione compounds (2004-02-24),

7. 6566364 - Linear or cyclic ureas (2003-05-20),

8. 6323217 - Piperidine-4 sulphonamide compounds (2001-11-27),

9. 5734077 - Substituted 2,2-dimethyl-omega-phenoxyalkanoic acids and esters (1998-03-31),

10. 5627205 - Substituted phenoxyisobutyric acids and esters (1997-05-06),

11. 5569647 - Angiopeptin cyclopeptide compounds (1996-10-29),

12. 5565457 - Substituted sulfonamides (1996-10-15),

13. 5512595 - Substituted phenoxyisobutyric acids and esters (1996-04-30),

14. 5457103 - 3',5'-di-tert.-butyl-4'-hydroxy flavones (1995-10-10),

15. 5389644 - 1,4-dihydropyridine compounds (1995-02-14),

Title: Jean-Paul Vilaine: Innovator in Medicinal Chemistry

Introduction

Jean-Paul Vilaine, based in Chatenay Malabry, France, is a prominent inventor in the field of medicinal chemistry. With an impressive portfolio of 28 patents, he has made significant contributions to the development of pharmaceutical compounds that address various health conditions.

Latest Patents

Among his latest innovations, Vilaine has developed isoquinoline compounds, along with procedures for their synthesis and formulations containing these substances. These compounds are particularly relevant for creating medicinal products that aid in treating or preventing pathologies linked to the activation of the RhoA/ROCK pathway and the phosphorylation of the myosin light chain. Additionally, he has worked on 1,2,4,5-tetrahydro-3H-benzazepine compounds, which also include a detailed process for their preparation and pharmaceutical compositions useful in treating a variety of medical conditions.

Career Highlights

Vilaine’s career is marked by his association with notable companies such as Adir Et Compagnie and Les Laboratoires Servier. His work within these organizations has been pivotal in advancing research and product development in the field of pharmaceuticals.

Collaborations

Throughout his career, Vilaine has collaborated with distinguished professionals, including Jean-Louis Peglion and Nicole Villeneuve. These partnerships have allowed for the exchange of innovative ideas and the advancement of research projects aimed at creating effective medicinal solutions.

Conclusion

Jean-Paul Vilaine stands out as a key figure in medicinal chemistry, evidenced by his extensive patent portfolio and collaborations. His ongoing contributions to the pharmaceutical industry continue to pave the way for new treatments and advancements in healthcare.

Profile summary based on public USPTO records.